These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 27554534)

  • 21. Serologic Response of 2 Versus 3 Doses and Intradermal Versus Intramuscular Administration of a Licensed Rabies Vaccine for Preexposure Prophylaxis.
    Endy TP; Keiser PB; Wang D; Jarman RG; Cibula D; Fang H; Ware L; Abbott M; Thomas SJ; Polhemus ME
    J Infect Dis; 2020 Apr; 221(9):1494-1498. PubMed ID: 31802120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An immunogenicity, safety and post-marketing surveillance of a novel adsorbed human diploid cell rabies vaccine (Rabivax) in Indian subjects.
    Sudarshan MK; Bhardwaj S; Mahendra BJ; Sharma H; Sanjay TV; Ashwathnarayana DH; Bilagumba G
    Hum Vaccin; 2008; 4(4):275-9. PubMed ID: 18682695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of purified Vero cell rabies vaccine manufactured in Pakistan: a comparative analysis of intradermal and intramuscular routes.
    Ali W; Ismail Tajik M; Ali I; Gul A; Khan JZ
    Curr Med Res Opin; 2023 May; 39(5):789-796. PubMed ID: 37011066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children.
    Angsuwatcharakon P; Khomvilai S; Limsuwun K; Ratananpinit N; Khamchat A; Sanitnai T; Tantawichien T
    Expert Rev Vaccines; 2018 Feb; 17(2):185-188. PubMed ID: 29285961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A serum-free, purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab for pre-exposure use in healthy adults: results from a randomized controlled phase-II trial.
    Pichon S; Guinet-Morlot F; Minutello M; Donazzolo Y; Rouzier R; Chassard D; Fitoussi S; Hou V
    Vaccine; 2013 Apr; 31(18):2295-301. PubMed ID: 23510665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of saftey and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML.
    Madhusudana SN; Sanjay TV; Mahendra BJ; Sudarshan MK; Narayana DH; Giri A; Muhamuda K; Ravi V; Vakil HB; Malerczyk C
    Hum Vaccin; 2006; 2(5):200-4. PubMed ID: 17035734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis.
    Ravish HS; Vijayashankar V; Madhusudana SN; Sudarshan MK; Narayana DH; Andanaiah G; Ashwin BY; Rachana AR; Shamanna M
    Hum Vaccin Immunother; 2014; 10(8):2433-7. PubMed ID: 25424951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-exposure prophylaxis (PEP) for rabies with purified chick embryo cell vaccine: a systematic literature review and meta-analysis.
    Preiss S; Chanthavanich P; Chen LH; Marano C; Buchy P; van Hoorn R; Vonk Noordegraaf M; Mukherjee P
    Expert Rev Vaccines; 2018 Jun; 17(6):525-545. PubMed ID: 29939085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (Abhayrab) manufactured in India.
    Sampath G; Reddy SV; Rao ML; Rao YU; Palaniappan C
    Vaccine; 2005 Jan; 23(7):897-900. PubMed ID: 15603890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis.
    Wang LY; Sun MP; Zhang XC; Suo LD; Xu RH; Zou YJ; Zuo LB; Qi H
    Vaccine; 2011 Mar; 29(15):2679-81. PubMed ID: 21296694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of a Novel Human Rabies Monoclonal Antibody to Human Rabies Immunoglobulin for Postexposure Prophylaxis: A Phase 2/3, Randomized, Single-Blind, Noninferiority, Controlled Study.
    Gogtay NJ; Munshi R; Ashwath Narayana DH; Mahendra BJ; Kshirsagar V; Gunale B; Moore S; Cheslock P; Thaker S; Deshpande S; Karande S; Kumbhar D; Ravish HS; Harish BR; Pisal SS; Dhere R; Parulekar V; Blackwelder WC; Molrine DC; Kulkarni PS
    Clin Infect Dis; 2018 Jan; 66(3):387-395. PubMed ID: 29020321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV).
    Shanbag P; Shah N; Kulkarni M; Juvekar M; Madhusudana SN; Vakil HB; Malerczyk C
    Hum Vaccin; 2008; 4(5):365-9. PubMed ID: 18398307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™.
    Vescovo P; Rettby N; Ramaniraka N; Liberman J; Hart K; Cachemaille A; Piveteau LD; Zanoni R; Bart PA; Pantaleo G
    Vaccine; 2017 Mar; 35(14):1782-1788. PubMed ID: 28317660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India.
    Sudarshan MK; Narayana DH; Madhusudana SN; Holla R; Ashwin BY; Gangaboraiah B; Ravish HS
    Hum Vaccin Immunother; 2012 Aug; 8(8):1077-81. PubMed ID: 22699446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen.
    Madhusudana SN; Sanjay TV; Mahendra BJ; Suja MS
    Int J Infect Dis; 2004 May; 8(3):175-9. PubMed ID: 15109593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience.
    Toovey S
    Travel Med Infect Dis; 2007 Nov; 5(6):327-48. PubMed ID: 17983973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postexposure rabies prophylaxis completed in 1 week: preliminary study.
    Shantavasinkul P; Tantawichien T; Wilde H; Sawangvaree A; Kumchat A; Ruksaket N; Lohsoonthorn V; Khawplod P; Tantawichien T
    Clin Infect Dis; 2010 Jan; 50(1):56-60. PubMed ID: 19995217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines.
    Quiambao BP; Lang J; Vital S; Montalban CG; Le Mener V; Wood SC; Miranda E
    Acta Trop; 2000 Feb; 75(1):39-52. PubMed ID: 10708006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen.
    Kalimuddin S; Wijaya L; Chan YFZ; Wong AWL; Oh HML; Wang LF; Kassim JA; Zhao J; Shi Z; Low JG
    Vaccine; 2017 Dec; 35(51):7127-7132. PubMed ID: 29174316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Comparative Study on the Adverse Reactions of Purified Chick Embryo Cell Vaccine (PCECV) and Purified Vero Cell Rabies Vaccine (PVRV).
    Ramezankhani R; Shirzadi MR; Ramezankhani A; Poor Mozafary J
    Arch Iran Med; 2016 Jul; 19(7):502-7. PubMed ID: 27362245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.